Xilio Therapeutics Income Statement (2020-2026) | XLO

Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
2.36M2.26M1.72M2.93M8.08M19.07M13.69M12.65M
Operating items
Research & Development (Quarter)
17.75M10.47M11.35M14.92M16.25M13.04M15.00M16.13M13.22M11.05M11.74M10.40M11.22M10.76M8.84M8.27M15.33M14.32M18.12M19.83M
Selling, General & Administrative (Quarter)
5.26M5.49M8.20M6.30M8.31M7.17M8.17M7.39M6.90M6.31M6.39M6.14M5.82M6.31M6.52M8.52M7.12M6.67M7.40M6.93M
Restructuring Costs (Quarter)
0.95M0.03M-0.04M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
23.01M15.96M19.56M21.22M24.55M20.21M23.17M23.53M20.12M17.36M18.13M17.49M17.06M17.02M15.35M16.78M22.45M21.00M25.52M26.76M
Operating Income (Quarter)
-23.01M-15.96M-19.56M-21.22M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
EBIT (Quarter)
-23.01M-15.96M-19.56M-21.22M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
Non-operating items
Other Non Operating Income (Quarter)
-0.17M-0.29M-0.14M-0.13M-0.06M0.42M0.70M0.88M0.76M0.61M0.47M0.28M0.78M0.74M0.54M0.59M-1.43M1.02M0.92M1.28M
Non Operating Income (Quarter)
-0.17M-0.29M-0.14M-0.13M-0.06M0.42M0.70M0.88M0.76M0.61M0.47M0.28M0.78M0.74M0.54M0.59M-1.48M-14.36M0.92M4.58M
Net income details
EBT (Quarter)
-23.01M-16.25M-19.70M-21.35M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
Profit After Tax (Quarter)
-23.18M-16.25M-19.70M-21.35M-24.61M-19.79M-22.40M-22.60M-19.36M-16.75M-17.70M-17.20M-13.93M-14.02M-13.14M-13.27M-14.37M-1.93M-11.84M-14.11M
Income from Continuing Operations (Quarter)
-23.01M-16.25M-19.70M-21.35M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
Consolidated Net Income (Quarter)
-23.01M-16.25M-19.70M-21.35M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
Income towards Parent Company (Quarter)
-23.01M-16.25M-19.70M-21.35M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
Net Income towards Common Stockholders (Quarter)
-23.01M-16.25M-19.70M-21.35M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M
Additional items
EPS (Basic) (Quarter)
-31.48-21.2762.66-0.78-0.90-0.72-0.82-0.83-0.70-0.61-0.64-0.62-0.24-0.22-14.33-2.49-0.16-0.11-3.76-0.58
EPS (Weighted Average and Diluted) (Quarter)
-31.48-21.2762.66-0.78-0.90-0.72-0.82-0.83-0.70-0.61-0.64-0.62-0.24-0.22-14.33-2.49-0.16-0.11-3.76-0.58
Shares Outstanding (Weighted Average) (Quarter)
0.72M0.76M5.61M27.37M27.38M27.38M27.39M27.43M27.47M27.48M27.50M27.91M42.84M19.51M3.82M25.60M92.28M92.28M4.24M16.35M
Shares Outstanding (Diluted Average) (Quarter)
0.74M0.76M5.61M27.37M27.38M27.38M27.39M27.43M27.47M27.52M27.50M27.91M42.84M63.47M3.82M5.34M96.45M105.34M8.36M16.35M
EBITDA (Quarter)
-23.18M-16.25M-19.70M-21.35M-24.61M-19.79M-22.47M-22.65M-19.36M-16.75M-17.66M-17.20M-13.93M-14.02M-13.09M-13.27M-15.84M-16.29M10.36M-9.53M
Interest Expenses (Quarter)
0.29M0.14M0.13M